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Abstract
Each of the effector CD4 T-cell lineages - Th1, Th2, and the more recently identified Th17 - arises
from pluripotent naïve precursors whose developmental fate is largely controlled by cytokines that
act in concert with antigenic signals. Remarkably, development of the Th17 lineage has been linked to
that of regulatory T cells, which obviate or downregulate Th17 responses to preserve immune
homeostasis, through a shared requirement for the cytokine transforming growth factor-beta. Several
new studies offer insights into the mechanism whereby the precursors of these subsets are directed
into distinct lineages.
Introduction and context
Transforming growth factor-beta (TGF-b) has long been a
poster child for pleiotropism in the cytokine world. The
diversity of cell types and regulatory processes over
which TGF-b holds influence reflects its longevity on the
phylogenetic stage and the evolutionary economy gained
by molecules that can be adapted for many cellular
processes. A common and often confounding feature of
the pleiotropy of TGF-b is its paradoxical ability to act in
the same pathway to opposite effects. This dualistic
nature of TGF-b has recently been extended to develop-
mental decisions that control alternative pathways of
CD4 T-cell differentiation. The discovery that there is a
shared requirement for TGF-b in the development of
anti-inflammatory regulatory T cells (Tregs) and pro-
inflammatory Th17 cells has provided an elegant
solution for linking the potentially pathogenic Th17
pathway with a potent counter-regulatory pathway that
can control it [1–4]. But this has also raised important
questions concerning how TGF-b might act at apparently
crossed purposes to do this. Several recent studies have
built on earlier observations to begin to provide a
mechanistic basis by which these two lineages, although
linked by a common requirement for TGF-b, go their
separate ways [5–9].
Differentiation of Th17 cells from antigen-naïve CD4
T-cell precursors, like the differentiation of Th1 and Th2
cells, is induced by cytokines emanating from innate
immune cells that have recognized specific pathogens. In
t h ec a s eo fT h 1 7 ,i n t e r l e u k i n( I L ) - 6p r o d u c e db y
dendritic cells (and perhaps other cells in the local
environment) acts in concert with active TGF-b to direct
Th17 differentiation. Th17 cells are largely defined by
their eponymous cytokines, IL-17A and IL-17F, whichare
pro-inflammatory by virtue of their direct and indirect
effects on neutrophil recruitment. In the absence of IL-6
(and thus pro-inflammatory cues from innate immune
cells), TGF-b promotes the differentiation of Tregs. Prior
to the discovery of Th17, Tregs had become defined by
a master transcription factor, Foxp3, which is both
necessary and sufficient to program Treg development
and maintenance. Following its discovery [10,11], the
Th17 lineage was soon linked to its own master
transcription factor, a T-cell isoform of the retinoic
acid-related orphan receptor g,R O R gt [12]. Interestingly,
however, naïve T cells stimulated with TGF-b alone were
found to upregulate both Foxp3 and RORgt, although
they failed to express an appreciable level of IL-17 and
progressively extinguished RORgt as they differentiated
into Tregs [8,13]. Similarly, early Th17 differentiation
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transient co-expression of RORgta n dF o x p 3 ,w i t h
Foxp3 extinguished as Th17 development progressed
[6,8]. These findings raised the possibility that Foxp3 and
RORgt might engage in an antagonistic competition, the
outcome of which could determine whether a cell
differentiated as a Treg or a Th17 cell.
Major recent advances
In fact, recent reports have indicated that this is indeed
the case, although not before introducing another player
into the mix. RORgt is one member of a three-member
family of nuclear receptors that also includes RORa and
RORb. Dong and colleagues [9] recently reported that
RORa, like RORgt, is expressed by Th17 cells, with
similar kinetics and similar functional effects. In the
original report linking RORgt to Th17, Littman and
colleagues [12] observed that mice deficient in RORgt
were largely Th17-deficient yet retained a small popula-
tion of Th17 cells. It now appears that RORa has at least
some redundant functions with RORgt and can partially
compensate for the absence of RORgt to drive Th17
development, although there appear to be differences in
the gene targets of these factors and these differences will
require further study [9].
The link between RORa and Th17 had been suggested by
an earlier report from Ziegler and colleagues [5], who
found that human Jurkat T cells transfected with RORa
expressed IL-17A and IL-22. Perhaps more importantly,
Ziegler and colleagues established that Foxp3 could
inhibit the transcriptional activity of RORa through
physical interaction of the two factors. In yeast two-
hybrid screens of a human Treg library that used Foxp3
as bait, RORa was identified as an interacting partner
and Foxp3 was shown to inhibit RORa activity through
direct interaction. A splice variant of Foxp3 that lacks
exon 2 was found to lack this repressive activity, and a
motif in exon 2 (LQALL, which is similar to the LxxLL
motif of other ROR co-activators and repressors) was
mapped that bound the carboxy-terminal AF2 domain of
RORa and was essential for its repression [5]. Thus, a
basis for direct suppression of an ROR factor by Foxp3
was established, and the domains mediating this
interaction were defined.
In a collaborative study, Ziegler's and Littman's groups
extended these findings, establishing similar interactions
between Foxp3 and RORgt in direct analyses of Th17
development in the mouse system [6]. In agreement with
the previous study of RORa [5], Foxp3 was found to
directly bind RORgt via exon 2 and repress its effects.
Moreover, repression of RORgt-mediated effects by
Foxp3 was critically dependent on the dose of TGF-b
used. High doses of TGF-b repressed RORgt function via
increased Foxp3; but at lower doses, TGF-b cooperated
with signals initiated by IL-6 to overcome Foxp3-
mediated repression of RORgt. Therefore, true to its
pleiotropic nature, TGF-b could drive fundamentally
different outcomes on the same cellular target via
differential effects of dose and co-signaling context. The
repressive effects of Foxp3 were dependent on both exon
2 and the DNA-binding forkhead domain in this study,
although the forkhead domain was dispensable in
another study [8].
In reciprocal fashion, the repressive effects of Foxp3
could be reversed by IL-6 as well as by IL-21 and IL-23,
which like IL-6 are STAT3-activating cytokines important
in Th17 differentiation. All of these cytokines both
suppress the expression of Foxp3 and attenuate its effects
under conditions of enforced expression. Similar find-
ings were independently reported by Ichiyama and
colleagues [7]. Thus, Th17-promoting cytokines may
act through STAT3-dependent pathways to reverse the
Foxp3-mediated repression of RORgt and RORa in
developing Th17 cells via both transcriptional and
post-transcriptional blockade of Foxp3.
In complementary studies, Yang and colleagues [8] used
dual-reporter mice that permit identification of IL-17F-
and Foxp3-positive T cells to demonstrate co-expression
of IL-17F and Foxp3 in a subset of Th17- or Treg-
polarized cells in vitro and in vivo. Remarkably, it was
shown that Tregs could express IL-17 and downregulate
Foxp3 if stimulated with IL-6, suggesting that mature
Tregs can be subverted to Th17-like cells late in their
development. Using mice with targeted deficiencies of
STAT3, RORg or RORa, or deficiency of both RORa and
RORg, Yang and colleagues [8] further demonstrated that
only STAT3-deficient mice failed to downregulate Foxp3
following IL-6 stimulation, whereas the RORg and RORa
mutants continued to inhibit Foxp3 despite greatly
reduced expression of IL17, indicating that the down-
regulation of Foxp3 by STAT3 activation is independent
of RORa or RORgt.
Future directions
Collectively, these studies support a model of divergent
Treg and Th17 differentiation in which early co-induc-
tion of the master transcription factors of both pathways
gives way to reciprocal amplification or suppression of
either Foxp3 or RORa and RORgt, contingent upon the
balance between local levels of active TGF-b or L-6
(Figure 1). Although specific details from these studies
are in conflict (for example, the requirement for the
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RORgt), there is remarkable concordance of most of
the major findings. Key questions remain, however.
What are the unique and redundant functions of RORa
and RORgt in the Th17 developmental pathway? Do
these orphan receptors require ligands for their function,
and if so, what are the ligands? Are these family members
co-expressed in the same cells or are they preferentially
expressed in emerging subsets of the Th17 lineage (for
example, IL-10-expressing or interferon-gamma-expres-
sing Th17 cells)? How is alternative splicing of exon 2 of
Foxp3 regulated, and how critical is this to the
derepression of RORa or RORgt? What are the cis-
regulatory sites targeted by these factors for activating or
suppressive effects on Th17- and Treg-associated gene
targets? Given the potential autoimmune dangers
inherent in the transition of Tregs to Th17 cells, how
often and under what circumstances might this conver-
sion occur physiologically, and what are the regulatory
implications of this late plasticity of the Treg pathway?
Clearly, insights into the pleiotropic roles for TGF-b in
regulating both Th17 and Treg pathways promise
additional surprises as these and other questions are
addressed in upcoming studies.
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Figure 1. Reciprocal development of Th17 and regulatory T cells
(Tregs) effected by the balance of Foxp3 and ROR transcription
factors.
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Naïve CD4 T cells activated by antigen (Ag) in the presence of transforming
growth factor-beta (TGF-b) induce co-expression of the transcription
factors Foxp3, RORa, and RORgt in early precursors fated for either Treg
or Th17 differentiation. Foxp3 binds to the ROR factors a and gt via a motif
in exon 2, repressing their transcriptional activity. Contingent upon the
balance of sustained levels of TGF-b or interleukin (IL)-6, Foxp3 expression
and repressive activity are enhanced or repressed, respectively, leading to
divergence of the Treg and Th17 pathways. In cells directed to the Th17
lineage, upregulation of the inducible component of the IL-23 receptor,
IL-23R, pairs with the constitutively expressed, shared IL-12 and IL-23
receptor component, IL-12Rb1, to confer responsiveness to IL-23, which
activates downstream aspects of the Th17 developmental program. Cells
directed to the induced Treg lineage express cytokine genes, such as Ebi3,
thatdistinguishthemfromthecytokinegenesexpressedbymatureTh17cells
(for example, Il17a and Il17f). ROR, retinoic acid-related orphan receptor;
RORgt, T-cell isoform of the retinoic acid-related orphan receptor g.
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